Trailing-twelve-month (TTM) revenue is $1.03 Billion with a year-over-year growth of +7.61%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-26 | $247,836,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-03 |
| Q4 FY2025Period ended 2025-12-31 | $258,349,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-23 |
| Q1 FY2026Period ended 2026-04-03 | $257,707,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-11 |
| Q2 FY2026Period ended 2026-07-03 | $265,807,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-05 |
| TTM revenue | $1,029,699,000 |
Current P/S: $5,410,337,908 market capitalization ÷ $1,029,699,000 TTM revenue = 5.25x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T17:15:10.000Z. Latest revenue period ended 2026-07-03.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-07-03): $265.81M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T17:17:30.839Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Advanced Surgery | N/A | N/A | N/A | N/A | $209M | $242M |
| Medical Solutions | N/A | N/A |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| CHINA | $71M | $95M | $97M | $73M | $85M | $93M |
| GERMANY | $84M | $102M | $134M | $128M |
$1.03B
$1.03 Billion
+7.61%
vs. $956.88M a year ago (TTM)
+10.65%
5 Year compound annual growth rate
1 Year
+7.61%
3 Year
+4.97%
5 Year
+10.65%
10 Year
+10.76%
15 Year
+6.94%
20 Year
+6.69%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $980.60M | +$31.36M | +3.30% |
| 2024 | $949.25M | +$67.58M | +7.67% |
| 2023 | $881.66M | +$20.76M | +2.41% |
| 2022 | $860.90M | +$154.11M | +21.80% |
| 2021 | $706.79M | +$116.17M | +19.67% |
| 2020 |
TTM Growth
+7.61%
3-Year CAGR
+4.97%
5-Year CAGR
+10.65%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T17:17:30.839Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| N/A |
| $325M |
| N/A |
| N/A |
| Photonics | $200M | $232M | $275M | N/A | N/A | N/A |
|---|
| Precision Manufacturing | N/A | N/A | N/A | N/A | $202M | $182M |
|---|
| Precision Medicine | N/A | N/A | N/A | N/A | $250M | $237M |
|---|
| Precision Medicine and Manufacturing | N/A | N/A | N/A | $283M | N/A | N/A |
|---|
| Precision Motion | $129M | $212M | $308M | N/A | N/A | N/A |
|---|
| Robotics and Automation | N/A | N/A | N/A | $273M | $288M | $319M |
|---|
| Vision | $262M | $262M | $278M | N/A | N/A | N/A |
|---|
| $115M |
| Other Countries | $9M | $11M | $18M | $19M | $18M | $19M |
|---|
| Rest Of Asia Pacific | $74M | $89M | $102M | $105M | $107M | $97M |
|---|
| Rest Of Europe | $127M | $139M | $138M | $137M | $129M | $137M |
|---|
| UNITED STATES | $226M | $271M | $372M | $418M | $487M | $519M |
|---|
| $590.62M |
| ($35.48M) |
| (5.67%) |
| 2019 | $626.10M | +$11.76M | +1.91% |
| 2018 | $614.34M | +$93.05M | +17.85% |
| 2017 | $521.29M | +$136.53M | +35.49% |
| 2016 | $384.76M | +$11.16M | +2.99% |
